4.3 Dental Pharmacology, Local Anesthetics & Medical Drug Considerations

4.3 Dental Pharmacology, Local Anesthetics & Medical Drug Considerations

Quick Answer: Dental local anesthetic agents prevent nociceptive nerve conduction by blocking voltage-gated sodium channels along nerve axons. They consist of a lipophilic aromatic ring, an intermediate chain, and a hydrophilic amine, categorized chemically into amides (metabolized in the liver; lidocaine, articaine, mepivacaine, bupivacaine, prilocaine) and esters (metabolized in blood plasma by pseudocholinesterases into allergenic PABA; procaine, benzocaine). Articaine is an amide with an additional ester linkage, enabling 90% to 95% rapid plasma clearance and a shorter elimination half-life. Vasoconstrictors (epinephrine) stimulate alpha-1 (α1) adrenergic receptors to produce local vasoconstriction, reducing bleeding, extending anesthesia, and decreasing systemic absorption; the Maximum Recommended Dose (MRD) is 0.2 mg (~11 cartridges of 1:100,000) for healthy adults and 0.04 mg (~2 cartridges of 1:100,000) for cardiovascular patients. Antibiotic prophylaxis (Amoxicillin 2.0 g orally 30–60 minutes pre-op) is restricted to highest-risk cardiac conditions for infective endocarditis; clindamycin is no longer recommended due to C. difficile colitis risks, and routine premedication is not recommended for prosthetic joint replacements. Major systemic medication concerns include anticoagulants (INR therapeutic range 2.0–3.0), antiresorptive drugs (MRONJ risk), and drug-induced gingival enlargement (phenytoin, calcium channel blockers, cyclosporine).

---

1. Local Anesthetic Chemistry: Amides vs. Esters

Local anesthetic molecules consist of three distinct structural components:

1. Lipophilic Aromatic Ring: Facilitates penetration through the lipid-rich perineural sheath and lipophilic neuronal membrane.
2. Intermediate Hydrocarbon Chain: Determines whether the drug is an amide (-NHCO-) or an ester (-COO-) linkage, dictating its biotransformation pathway.
3. Hydrophilic Tertiary Amine: Allows the molecule to dissolve in aqueous extracellular fluids, existing in dynamic equilibrium between the uncharged free base (RN) and the positively charged cation (RNH+).

                  LOCAL ANESTHETIC MECHANISM OF ACTION

     Extracellular Tissue Fluid (pH 7.4)           Neuronal Axoplasm (pH 7.4)
  ──────────────────────────────────────────   ───────────────────────────────
    Charged Cation      Uncharged Base            Uncharged Base   Charged Cation
       (RNH⁺)     ⇄         (RN)                       (RN)      ⇄     (RNH⁺)
                             │                          ▲              │
                             │ Diffuses across          │              ▼
                             └─── Lipid Nerve Membrane ─┘        Binds to Sodium
                                                                 Channel Receptor
                                                                       │
                                                                       ▼
                                                             Blocks Na⁺ Influx
                                                             Prevents Action Potential
                                                             Halts Pain Conduction

Mechanism of Action: The Sodium Channel Blockade

At physiological tissue pH (7.4), the uncharged, lipophilic free base (RN) crosses the lipid nerve membrane into the cell. Inside the axoplasm, the molecule picks up a hydrogen ion to become a charged cation (RNH+). The charged cation binds to a specific receptor site within the internal pore of voltage-gated sodium (Na+) channels, preventing sodium influx, halting membrane depolarization, and blocking pain transmission.

Clinical Acidosis & Infection Note: When injecting into infected or inflamed tissue (where tissue pH drops to 5.5 to 6.0), the acidic environment forces the equilibrium toward the charged cation form (RNH+). Lacking sufficient uncharged base (RN), the anesthetic cannot penetrate the nerve membrane, resulting in incomplete or failed local anesthesia.

Chemical Classification: Amides vs. Esters

                   CHEMICAL CLASSIFICATION OF LOCAL ANESTHETICS
┌────────────────────────────┬───────────────────────────────────────────────────┐
│ AMIDES (Two "i"s in Name)  │ ESTERS (One "i" in Name)                          │
├────────────────────────────┼───────────────────────────────────────────────────┤
│ • Lidocaine (Xylocaine)    │ • Procaine (Novocain)                             │
│ • Articaine (Septocaine)   │ • Benzocaine (Topical HurriCaine)                 │
│ • Mepivacaine (Carbocaine) │ • Tetracaine (Pontocaine)                         │
│ • Bupivacaine (Marcaine)   │ • Cocaine                                         │
│ • Prilocaine (Citanest)    │                                                   │
├────────────────────────────┼───────────────────────────────────────────────────┤
│ Biotransformation:         │ Biotransformation:                                │
│ • Primarily in LIVER by    │ • In BLOOD PLASMA by pseudocholinesterase enzymes │
│   cytochrome P450 enzymes  │ • Hydrolyzed into Para-Aminobenzoic Acid (PABA)   │
│ • Articaine: 90-95% plasma │ • HIGH ALLERGENIC POTENTIAL (PABA sensitivity)   │
│   pseudocholinesterase     │ • Esters rarely used as injectables today         │
│ • Allergic reactions RARE  │                                                   │
└────────────────────────────┴───────────────────────────────────────────────────┘

The Articaine Exception

Articaine (Septocaine, 4% with 1:100,000 or 1:200,000 epinephrine) is chemically unique: it contains both an intermediate amide linkage and an additional ester side chain attached to a thiophene ring. Because of this ester group, 90% to 95% of articaine is hydrolyzed rapidly in the blood plasma by pseudocholinesterase, with only 5% to 10% cleared by hepatic microsomal enzymes. Consequently, articaine possesses an exceptionally short elimination half-life (20 to 40 minutes, compared to 90 minutes for lidocaine), significantly lowering systemic drug accumulation during prolonged procedures.

Esters & Benzocaine Toxicity

Esters are metabolized in plasma to para-aminobenzoic acid (PABA), a known allergen responsible for contact dermatitis, urticaria, and anaphylactoid reactions. True injectable esters are virtually obsolete in modern dental operatories. However, benzocaine (20%) remains widely used as a topical mucosal anesthetic gel. Because benzocaine is an ester, excessive mucosal application or use in infants can trigger methemoglobinemia, an acute condition where iron in hemoglobin is oxidized from ferrous (Fe2+) to ferric (Fe3+), impairing oxygen release to tissues and causing slate-gray cyanosis, dyspnea, and lethargy.

---

2. Vasoconstrictors in Dental Anesthesia

Almost all dental local anesthetics are intrinsic vasodilators (mepivacaine and prilocaine dilate only mildly, and cocaine, a topical agent, is the only true vasoconstrictor) that relax vascular smooth muscle, accelerating their own clearance into the systemic bloodstream. To counteract this, vasoconstrictors—predominantly epinephrine (adrenaline) or levonordefrin (Neo-Cobefrin)—are added to anesthetic carpules.

Three Critical Clinical Roles of Vasoconstrictors

1. Hemostasis: Stimulates local vascular smooth muscle contraction, dramatically reducing bleeding in surgical and operative fields.
2. Prolonged Duration: Constricts local microvasculature, keeping the anesthetic molecule concentrated around the nerve axon, extending pulpal and soft-tissue anesthesia.
3. Reduced Toxicity: Retards the rate of vascular absorption into the general circulation, flattening peak plasma concentrations and lowering the risk of local anesthetic systemic toxicity (LAST).

Adrenergic Receptor Activity

• Alpha-1 (α1) Receptors: Located on vascular smooth muscle of oral submucosa; produces intense local arteriolar vasoconstriction.
• Beta-1 (β1) Receptors: Located primarily in cardiac myocardium; increases heart rate (positive chronotropic effect), stroke volume, and myocardial contractility (positive inotropic effect).
• Beta-2 (β2) Receptors: Located in skeletal muscle vessels and bronchiolar smooth muscle; produces bronchodilation and vasodilation.

Maximum Recommended Dose (MRD) Calculations

A standard dental anesthetic cartridge contains 1.8 mL of solution.

• 1:100,000 Epinephrine: Contains 0.01 mg/mL * 1.8 mL = 0.018 mg of epinephrine per cartridge.
• 1:200,000 Epinephrine: Contains 0.005 mg/mL * 1.8 mL = 0.009 mg of epinephrine per cartridge.
• 1:50,000 Epinephrine: Contains 0.02 mg/mL * 1.8 mL = 0.036 mg of epinephrine per cartridge (reserved strictly for surgical hemostasis).

                      EPINEPHRINE DOSING COMPARISON

     [ Healthy Adult Patient (ASA I) ]         [ Medically Compromised / Cardiac Patient ]
     Maximum Dose: 0.20 mg per visit           Maximum Dose: 0.04 mg per visit
     ───────────────────────────────           ─────────────────────────────────────────
     • 1:100,000 Carpules (0.018 mg/cart):     • 1:100,000 Carpules (0.018 mg/cart):
       0.20 / 0.018 ≈ 11.1 CARTRIDGES            0.04 / 0.018 ≈ 2.2 CARTRIDGES (Cap at 2)
     • 1:200,000 Carpules (0.009 mg/cart):     • 1:200,000 Carpules (0.009 mg/cart):
       0.20 / 0.009 ≈ 22.2 CARTRIDGES            0.04 / 0.009 ≈ 4.4 CARTRIDGES (Cap at 4)

The Cardiac Epinephrine Limit (0.04 mg)

The 0.04 mg cardiac dose applies to patients with:

• Significant cardiovascular disease (ischemic heart disease, coronary artery disease, heart failure).
• History of myocardial infarction (MI) or stroke (>6 months ago; elective care avoided <6 months).
• Severe or poorly controlled hypertension (e.g., Blood Pressure >= 160/100 mmHg).
• Patients taking non-selective beta-blockers (e.g., propranolol, nadolol): Unopposed alpha-1 stimulation by epinephrine causes severe peripheral vasoconstriction, triggering life-threatening hypertensive crises and compensatory reflex bradycardia.

Plain (Vasoconstrictor-Free) Anesthetic Formulations

• 3% Mepivacaine Plain (Carbocaine / Scandonest): Possesses the least intrinsic vasodilating properties of all dental amides. Provides reliable pulpal anesthesia (20 to 40 minutes) without vasoconstrictor, making it the premier choice for cardiac patients and short pediatric procedures.
• 4% Prilocaine Plain (Citanest Plain): Provides effective infiltration and nerve block anesthesia without epinephrine.

---

3. Local Anesthetic Systemic Toxicity (LAST)

Local anesthetic systemic toxicity is a life-threatening adverse reaction caused by excessive plasma drug levels, resulting from accidental intravascular injection (failure to aspirate) or cumulative overdose exceeding maximum safe milligrams per kilogram.

                   CLINICAL PROGRESSION OF SIGNS & SYMPTOMS IN LAST

     [ PHASE 1: Initial / Mild CNS Stimulation ]
     • Circumoral / perioral numbness and tongue tingling
     • Metallic taste in mouth
     • Lightheadedness, tinnitus (ringing/buzzing in ears), slurred speech, agitation
                            │
                            ▼
     [ PHASE 2: Moderate CNS Excitation ]
     • Involuntary muscle twitching, shivering, facial tremors
     • Generalized tonic-clonic seizures
                            │
                            ▼
     [ PHASE 3: Severe CNS & Cardiovascular Collapse ]
     • Generalized CNS depression, loss of consciousness, coma, respiratory arrest
     • Profound bradycardia, hypotension, heart block, ventricular arrhythmias
     • Asystole (cardiovascular collapse)

Prevention & Emergency Management of LAST

• Aspiration Protocol: Always use an aspirating syringe and aspirate in two anatomical planes (rotating the barrel 45 degrees) prior to and periodically during injection.
• Slow Injection Rate: Inject slowly, at about 1 mL per minute, so a full 1.8 mL cartridge takes roughly 2 minutes.
• Emergency Actions:
  1. Immediately discontinue the local anesthetic injection.
  2. Call 911 / emergency code.
  3. Position the patient supine with feet slightly elevated; administer 100% high-flow oxygen.
  4. Protect the patient from physical trauma during tonic-clonic seizures; maintain airway patency.
  5. Activate advanced cardiac life support (ACLS); prepare for intravenous administration of 20% lipid emulsion therapy (Intralipid), which acts as a "lipid sink" to extract lipophilic local anesthetics from myocardial and cerebral tissues.

---

4. Dental Analgesics: Non-Opioid and Opioid Options

Postoperative dental pain is primarily inflammatory, initiated by tissue trauma that triggers the arachidonic acid cascade.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

• Mechanism: Inhibit cyclooxygenase enzymes (COX-1 and COX-2), blocking the conversion of arachidonic acid into pro-inflammatory and pain-sensitizing prostaglandins (PGE2).
• Clinical Status: First-line gold standard for acute odontogenic pain. Clinical trials demonstrate that ibuprofen 400 to 600 mg taken every 4 to 6 hours is significantly more effective at relieving dental inflammatory pain than opioid monotherapy.
• Adverse Effects: Gastric irritation, peptic ulceration, and GI bleeding (due to COX-1 inhibition reducing protective gastric mucus); reversible inhibition of platelet aggregation; renal vasoconstriction.
• Contraindications: Active peptic ulcer disease, severe renal insufficiency, third trimester of pregnancy (causes premature closure of the fetal ductus arteriosus), and aspirin-sensitive asthma (Samter's triad).

Acetaminophen (Paracetamol / Tylenol)

• Mechanism: Acts primarily within the central nervous system to inhibit prostaglandin synthesis; provides analgesic and antipyretic relief, but lacks significant peripheral anti-inflammatory activity.
• Clinical Indications: Premier alternative for patients with NSAID contraindications (gastric ulcers, bleeding diatheses, anticoagulant therapy, aspirin allergy, pregnancy).
• Dosage Considerations: Adult maximum daily dose is 4,000 mg per 24 hours (many clinical advisories recommend an operating limit of 3,000 mg/day; capped at 2,000 mg/day in patients with chronic alcohol abuse or hepatic disease).
• Toxicity: Overdose saturates normal hepatic glucuronidation and sulfation pathways, shunting drug metabolism to CYP2E1, which produces the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI). NAPQI depletes hepatic glutathione, causing acute centrilobular hepatic necrosis and liver failure. Antidote: Intravenous or oral N-acetylcysteine (NAC).

The Synergistic Regimen: For severe acute dental pain, alternating or combining ibuprofen (400–600 mg) with acetaminophen (500–1000 mg) every 4 to 6 hours achieves pain relief superior to opioid combinations (e.g., codeine or oxycodone) with fewer adverse side effects.

Opioid Analgesics

• Mechanism: Agonists at central mu-opioid (μ) receptors, altering the perception and emotional response to pain.
• Formulations: Typically combined with acetaminophen (e.g., Tylenol #3 containing 300 mg acetaminophen + 30 mg codeine).
• Adverse Effects: Nausea, vomiting, sedation, dizziness, constipation, respiratory depression, physical tolerance, and high potential for dependence and abuse.

---

5. Antibiotic Prophylaxis Guidelines: CDA and AHA Standards

Infective Endocarditis (IE) Prophylaxis

Infective endocarditis is a life-threatening infection of the cardiac endothelium or heart valves caused by bacteremia from oral microorganisms (notably Viridans group streptococci). Under Canadian Dental Association (CDA) and American Heart Association (AHA) guidelines, prophylaxis is indicated exclusively for patients with the highest risk of adverse outcomes from IE.

Indications for IE Prophylaxis (Highest-Risk Conditions ONLY)

1. Prosthetic cardiac valves or prosthetic material used for cardiac valve repair.
2. Previous documented history of infective endocarditis.
3. Unrepaired cyanotic congenital heart disease (CHD), including palliative shunts and conduits.
4. Completely repaired congenital heart defect with prosthetic material or device during the first 6 months following the procedure.
5. Repaired CHD with residual defects at or adjacent to the site of a prosthetic patch or prosthetic device.
6. Cardiac transplant recipients who develop cardiac valvulopathy.

Conditions NO LONGER Requiring Prophylaxis: Mitral valve prolapse (with or without regurgitation), rheumatic heart disease, bicuspid aortic valve disease, calcified aortic stenosis, coronary artery stents, and implanted pacemakers or defibrillators.

Dental Procedures Requiring Prophylaxis

Prophylaxis is indicated for all dental procedures involving manipulation of gingival tissues, manipulation of the periapical region of teeth, or perforation of the oral mucosa (scaling, periodontal probing, extractions, biopsy, subgingival cord placement).

• NOT Indicated For: Routine local anesthetic injections through non-infected tissue, dental radiographs, placement of removable prostheses or orthodontic appliances, shedding of deciduous teeth, or bleeding from trauma to the lips/oral mucosa.

Antibiotic Dosing Regimens for IE Prophylaxis

                    ANTIBIOTIC PROPHYLAXIS REGIMENS FOR IE
┌──────────────────────────────────────┬─────────────────────────────────────────┐
│ Clinical Situation                   │ Antibiotic Regimen (Single Dose 30-60m) │
├──────────────────────────────────────┼─────────────────────────────────────────┤
│ Standard Oral Regimen                │ Amoxicillin 2.0 g orally                │
│ (No Penicillin Allergy)              │ (Pediatric: 50 mg/kg orally)            │
├──────────────────────────────────────┼─────────────────────────────────────────┤
│ Penicillin Allergy (Oral)            │ • Cephalexin 2.0 g orally (50 mg/kg)*   │
│                                      │ • Azithromycin 500 mg orally (15 mg/kg) │
│                                      │ • Clarithromycin 500 mg orally (15 mg/kg│
│                                      │ • Doxycycline 100 mg orally             │
├──────────────────────────────────────┼─────────────────────────────────────────┤
│ Unable to Take Oral Medication       │ • Ampicillin 2.0 g IM or IV             │
│                                      │ • Cefazolin or Ceftriaxone 1.0 g IM/IV  │
└──────────────────────────────────────┴─────────────────────────────────────────┘
*Cephalexin should only be used if the penicillin allergy was non-anaphylactic (no history of anaphylaxis, angioedema, or urticaria).

CRITICAL PRACTICE UPDATE: Clindamycin is NO LONGER recommended by the AHA and CDA guidelines for antibiotic prophylaxis due to an unacceptably high risk of severe, potentially fatal adverse reactions—specifically Clostridioides difficile (C. diff) pseudomembranous colitis, which can develop even after a single prophylactic dose.

Total Joint Replacement Prophylaxis Consensus

Based on the 2016 Canadian consensus statement (Association of Medical Microbiology and Infectious Disease Canada, Canadian Orthopaedic Association and Canadian Dental Association) and the ADA's 2015 clinical practice guideline:

• Routine prophylactic antibiotics are NOT recommended prior to dental procedures for patients with prosthetic joint implants (total hip, knee, or shoulder arthroplasties).
• The available evidence does not show that dental procedures cause prosthetic joint infections.
• Antibiotic premedication is considered only if specifically requested or prescribed by the patient's orthopedic surgeon for high-risk, severely immunocompromised individuals (e.g., active rheumatoid arthritis, systemic lupus erythematosus, immunosuppression following organ transplantation).

---

6. Systemic Medications and Dental Implications

                 COMMON MEDICAL DRUGS REQUIRING DENTAL PRECAUTIONS

     [ Anticoagulants / Antiplatelets ]         [ Antiresorptives / Bisphosphonates ]
     • Warfarin (Target INR: 2.0 - 3.0)        • Oral: Alendronate (Fosamax)
     • DOACs: Apixaban, Rivaroxaban             • IV: Zoledronic acid; SC: Denosumab  
     • Antiplatelets: Aspirin, Plavix          • Risk: MRONJ (>8 wks exposed bone)
     • Action: DO NOT STOP without MD OK;      • Action: Complete dental work prior to
       use local hemostatics (Surgicel, Gelfoam)  therapy; avoid invasive extractions
                           ╲                 ╱
                            ╲               ╱
                             ▼             ▼
                        [ Gingival Hyperplasia Agents ]
                        • Anticonvulsant: Phenytoin (Dilantin)
                        • Calcium Channel Blocker: Nifedipine, Amlodipine
                        • Immunosuppressant: Cyclosporine
                        • Action: Plaque control; gingivectomy; drug substitution

Anticoagulants and Antiplatelets

1. Warfarin (Coumadin): Vitamin K antagonist that inhibits clotting factors II, VII, IX, and X. Monitored via the International Normalized Ratio (INR).
   • Therapeutic INR Target: The standard target for patients on warfarin is an INR of 2.0 to 3.0 (or 2.5 to 3.5 for mechanical prosthetic heart valves).
   • Dental Protocol: Minor oral surgical procedures (simple extractions, periodontal debridement) can be safely performed without discontinuing warfarin if the INR is within therapeutic range (<3.5), verified within 24 to 72 hours of surgery. Bleeding is managed with local hemostatic measures (tranexamic acid 4.8% mouthwash, oxidized regenerated cellulose [Surgicel], absorbable gelatin sponge [Gelfoam], resorbable sutures, and direct gauze compression).
2. Direct Oral Anticoagulants (DOACs): Direct factor Xa inhibitors (Apixaban/Eliquis, Rivaroxaban/Xarelto) or direct thrombin inhibitors (Dabigatran/Pradaxa). They have predictable pharmacokinetics, rapid onset, short half-lives, and do not require routine INR monitoring. Discontinuing DOACs for routine dental procedures is generally unnecessary and increases stroke risk.
3. Antiplatelet Agents (Aspirin, Clopidogrel/Plavix): Irreversibly inhibit platelet aggregation for the lifespan of the platelet (7 to 10 days). Antiplatelets must never be discontinued prior to dental care without express written authorization from the treating cardiologist due to the catastrophic risk of acute coronary stent thrombosis and myocardial infarction.

Antiresorptive Medications and MRONJ

• Medications: Bisphosphonates (oral: alendronate/Fosamax; IV: zoledronic acid/Zometa, pamidronate/Aredia) and RANKL inhibitors (subcutaneous: denosumab/Prolia/Xgeva). Prescribed for osteoporosis, Paget's disease, and bone metastases of cancer.
• Medication-Related Osteonecrosis of the Jaw (MRONJ): Clinically diagnosed when all three criteria are met:
  1. Exposed, necrotic bone or bone probed through an intraoral or extraoral fistula in the maxillofacial region that has persisted for more than 8 weeks.
  2. Current or previous treatment with antiresorptive or antiangiogenic agents.
  3. No history of radiation therapy to the jaws or metastatic disease to the jaws.
• Clinical Management: The risk of MRONJ is low with oral bisphosphonates (<0.1%), but substantial with high-dose intravenous therapy (1% to 15%). The primary trigger is invasive dentoalveolar surgery (tooth extractions). Whenever possible, non-surgical endodontic therapies are preferred over extractions. Patients scheduled to begin IV antiresorptive therapy must receive comprehensive dental screening and complete all required extractions prior to starting therapy.

Drug-Induced Gingival Enlargement (Overgrowth)

Three classic drug classes provoke fibrous gingival hyperplasia by altering fibroblast collagen metabolism:

1. Anticonvulsants: Phenytoin (Dilantin), used for epilepsy; produces gingival overgrowth in up to 50% of patients.
2. Calcium Channel Blockers: Nifedipine (Adalat/Procardia), Amlodipine (Norvasc), and verapamil, used for hypertension and angina pectoris.
3. Immunosuppressants: Cyclosporine (Sandimmune/Neoral), used to prevent organ transplant rejection.

• Clinical Presentation: Painless, firm, lobulated, fibrous enlargement starting at the interdental papillae and progressing across facial and lingual surfaces of the teeth. While drug-induced, the condition is severely exacerbated by local plaque accumulation.
• Dental Management: Meticulous plaque control, frequent professional cleanings, surgical gingivectomy or gingivoplasty for functional or aesthetic impairment, and medical consultation with the physician to explore drug substitution (such as switching calcium channel blockers to an ACE inhibitor or ARB).

---

7. Comparative Pharmacology Reference Table